Karwyn S. Gustafson, RN, MSN
University of New Mexico Comprehensive Cancer CenterAlbuquerque, NMAuthored Items
Karwyn S. Gustafson, RN, MSN, Francisco J. Esteva, MD, PhD, Peter Jiang, MD, J. Thaddeus Beck, MD, Dennis J. Slamon, MD, PhD
November 2018 Vol 9, NO 11
Ribociclib combined with an aromatase inhibitor has been shown to significantly prolong progression-free survival (PFS) in premenopausal and postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced breast cancer (ABC) who had not been treated previously for ABC.
Last modified: December 19, 2018